NP Thyroid 60
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- NP Thyroid 60
- Generic name
- LEVOTHYROXINE, LIOTHYRONINE
- Manufacturer
- NuCare Pharmaceuticals,Inc,
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 231da0d9-b994-5201-e063-6394a90a78c6
- SPL ID
- 231db3bd-7a08-dd2a-e063-6394a90a8ce2
- Version
- 1
- Effective date
- 2024-09-27
- Source export date
- 2026-09-28
- Source partition
- 9
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0009-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/6784607726c827491ceaeab30d843632e0660ee8008c535197be5ed9e1e52201/drug-label-0009-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:04:04
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | NP Thyroid 60 | openfda.brand_name | |
| generic name | LEVOTHYROXINE, LIOTHYRONINE | openfda.generic_name | |
| manufacturer name | NuCare Pharmaceuticals,Inc, | openfda.manufacturer_name | |
| ndc | package | 68071-3691-3 | openfda.package_ndc |
| ndc | product | 68071-3691 | openfda.product_ndc |
| ndc11 | package | 68071369103 | derived:openfda.package_ndc |
| rxcui | 313391 | openfda.rxcui | |
| rxcui | 1724481 | openfda.rxcui | |
| spl id | 231db3bd-7a08-dd2a-e063-6394a90a8ce2 | id | |
| spl set id | 231da0d9-b994-5201-e063-6394a90a78c6 | set_id | |
| unii | 06LU7C9H1V | openfda.unii | |
| unii | Q51BO43MG4 | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings
WARNINGS
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS: Adverse reactions other than those indicative of hyperthyroidism because of therapeutic overdosage, either initially or during the maintenance period, are rare (See OVERDOSAGE).
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.